Rockland and LIMR Expand Licensing and Commercialization Relationship
Tuesday, October 30, 2012
Rockland will market established technologies including the CellCountEZ®, OxPhos™, RadDose™ and the Intracellular ThiolEZ™ assays.
£0.5 Million DHT Boost for Humane Research
Monday, October 29, 2012
Call for applications for next wave of grant funding also announced.
Discovery of Biological Energy-Sensing Switch Could Have Broad Implications for Biology and Medicine
Tuesday, October 23, 2012
Biochemists at The Scripps Research Institute (TSRI) have discovered a genetic sequence that can alter its host gene’s activity in response to cellular energy levels.
A Declaration of Openness in Using Animals in Research
Monday, October 22, 2012
The MRC and other members of the research sector have signed a declaration on transparency in animal research.
Absorption, Tolerability and Safety Study for Novel Antibacterial Compound Completed
Friday, October 19, 2012
Ferrer announced it has successfully completed a clinical trial, in adult and juvenile patients with impetigo, involving Ozenoxacin formulated as a topical treatment.
Charles River Laboratories Enters Strategic Partnership with AstraZeneca
Friday, October 19, 2012
Global CRO partners with global biopharmaceutical company to accelerate drug development.
SAGE® Labs, Ekam Imaging, Inc. Partner on Preclinical Imaging Assays
Friday, October 19, 2012
Companies to develop a suite of preclinical services based on the advanced translational power of genetically engineered rat models from SAGE Labs and Ekam's expertise in functional magnetic resonance imaging (fMRI) technology.
Synthetic Liver Enzyme Could Result in More Effective Drugs with Fewer Side Effects
Tuesday, October 16, 2012
Medicines could be made to have fewer side effects and work in smaller doses with the help of a new technique that makes drug molecules more resistant to breakdown by the human liver.
Tissue of Origin Determines Cancer-associated CpG Island Promoter Hypermethylation Patterns
Friday, October 05, 2012
Meehan, Sproul and co-workers conclude that general aberrant promoter hypermethylation in cancer does not promote tumorigenesis, but instead reinforces transcription repression inherited from pre-cancerous tissue.
|
|
|
|
|
|
